CoChat

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil

Open access
Cerqueira-Silva, Thiago, de Araujo Oliveira, Vinicius, Paixão, Enny S., Júnior, Juracy Bertoldo, Penna, Gerson O., Werneck, Guilherme L., Pearce, Neil, Barreto, Maurício L., Boaventura, Viviane S., Barral-Netto, Manoel · 2022 · Nature Communications
Cited by 48

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

To date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine effectiveness (VE) of CoronaVac plus BNT162b2 booster during the period of dominance of the Omicron variant in Brazil (January to April 2022). Using a test-negative design, we analysed data for 2,471,576 individuals tested during the Omicron variant’s dominant period using a nationally linked database from Brazil. Compared to unvaccinated, vaccinees maintained protection against severe outcomes, with an estimated VE of 84.1% (95% CI:83.2–84.9) at more than 120 days after BNT162b2 booster. Furthermore, while we detected a high level of protection against severe outcomes for individuals up to 79 years old, waning was observed for individuals aged ≥80 years, with VE decreasing from 81.3% (95% CI:77.9–84.2) at 31–60 days to 72.9% (95% CI:70.6–75.1) at 120 days or more after the booster dose. However, no significant protection against symptomatic infection was observed at this time period. In conclusion, except for individuals aged ≥80 years, CoronaVac plus a BNT162b2 booster dose offered high and durable protection against severe outcomes due to Omicron.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-31839-7

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 48

Metadata

Authors
Cerqueira-Silva, T., de Araujo Oliveira, V., Paixão, E. S., Júnior, J. B., Penna, G. O., Werneck, G. L., Pearce, N., Barreto, M. L., Boaventura, V. S., & Barral-Netto, M.
Venue
Nature Communications
Published
2022-07-18
Volume
13
Issue
1
Pages
4154-4154
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4285803421
Cited by
48
References
7
FWCI
5.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. https://app.cochat.ai/papers/10.1038/s41467-022-31839-7
The paper
Cerqueira-Silva, T., de Araujo Oliveira, V., Paixão, E. S., Júnior, J. B., Penna, G. O., Werneck, G. L., Pearce, N., Barreto, M. L., Boaventura, V. S., & Barral-Netto, M. (2022). Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications. https://doi.org/10.1038/s41467-022-31839-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.